The absolute rate is still below 0.5%, in line with prior ablation studies, but the issue warrants monitoring, a researcher ...

There are both clinical and economic implications, as payers have been discouraging ablation in this population, one expert ...

CellFX marks another route for Afib ablation technology ...

Johnson & Johnson today announced the initiation of a new trial evaluating competitive pulsed field ablation (PFA) ...

Boston Scientific leads the pulsed field ablation (PFA) technology market to treat atrial fibrillation (Afib). But it is by no means alone in its commitment to this relatively new way to treat some ...

AVANT GUARD trial meets expectations despite pause for safety modifications ...

Johnson & Johnson has initiated the PERSIGMA randomized controlled trial (RCT), one of the first randomized studies ...

MARLBOROUGH, Mass., July 7, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use (IFU) ...

Treatment success with pulsed field ablation was higher at 1 year than with antiarrhythmic drug therapy for patients with persistent atrial fibrillation.

Please provide your email address to receive an email when new articles are posted on . The FDA approved an expanded indication for Boston Scientific’s pulsed field ablation catheter for refractory, ...

The study will compare outcomes on J&J’s Varipulse Pro platform and Boston Scientific’s rival Farapulse PFA system.

The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation MARLBOROUGH, Mass., July 7, 2025 /PRNewswire/ -- Boston Scientific ...